still for framstellning of prostaglandins of the pge type? 712 with foreningar type pga? as utgangsforeningar

摘要

Process comprises (1) oxidising 15 beta-PGA2 acetate methyl ester to corresp. alpha and beta 10,11 epoxide, (2) reducing the epoxides to a mixture of 15 beta-PGE2 and 11 beta, 15 beta-PGE2 15-acetate methyl esters, (3) separating the latter, (4) silylating the 15 beta-PGE2 15-acetate methyl ester to 15 beta-PGE2 11-O-Si-(CH3)3 ether 15-acetate methyl ester, (5) reducing the product from 4 and then hydrolysing to give the 15 beta PGF2 alpha and 15 beta-PGF2 beta-15 acetate methyl ester, (6) separating the mixture, (7) saponifying the 15 beta-PGF2 alpha 15-acetate methyl ester to 15 beta-PGF2 alpha, (8) oxidising the latter to 15-oxo-PGF2 alpha, (9) silylating the latter to 15-oxo-PGF2 alpha 9,11-Di-Si-(CH3)3 ether or the corresp. -Si(CH3)3 ester, (10) reducing the product from 9 and then hydrolysing to give PGF2 alpha/15 beta-PGF2 alpha which mixture is separated.